Secretion of [Met]Enkephalyl‐Arg6‐Phe7‐Related Peptides and Catecholamines from Bovine Adrenal Chromaffin Cells: Modification by Changes in Cyclic AMP and by Treatment with Reserpine
- 1 July 1987
- journal article
- Published by Wiley in Journal of Neurochemistry
- Vol. 49 (1), 208-215
- https://doi.org/10.1111/j.1471-4159.1987.tb03416.x
Abstract
Investigations into the effects of culturing bovine adrenal chromaffin cells in the presence (72 h) of dibutyryl cyclic AMP, forskolin, and reserpine on the level and release of [Met]enkephalyl-Arg6-Phe7 immunoreactivity, noradrenaline, and adrenaline are reported. The assay for [Met]enkephalyl-Arg6-Phe7 immunoreactivity recognises both peptide B, the 31-amino acid carboxy-terminal segment of proenkephalin, and its heptapeptide fragment, [Met]enkephalyl-Arg6-Phe7. Treatments that elevate cyclic AMP increase the amount of peptide immunoreactivity in these cells; this is predominantly peptide B-like immunoreactivity in both control cells and cyclic AMP-elevated cells. Treatment with reserpine gives no change in total immunoreactivity levels, but does not result in increased accumulation of the heptapeptide [Met]enkephalyl-Arg6-Phe7 at the expense of immunoreactivity that elutes with its immediate precursor, peptide B. Cyclic AMP treatment causes either no change or a decrease in levels of accumulated noradrenaline and adrenaline. However, the release of [Met]enkephalin-Arg6-Phe7 immunoreactivity, noradrenaline, and adrenaline is increased by 72-h pretreatment with forskolin or dibutyryl cyclic AMP, whether release is stimulated by nicotine or elevated potassium. In each case the molecular form of [Met]enkephalyl-Arg6-Phe7 immunoreactivity that is released approximately reflects the cell content. Pretreatment with reserpine has no effect on the total [Met]enkephalyl-Arg6-Phe7 immunoreactivity released, but does result in an increased release of the heptapeptide and a decrease in release of peptide B-like immunoreactivity. The studies suggest that the levels of [Met]enkephalyl-Arg6-Phe7 and peptide B available for release are controlled both at the level of proenkephalin synthesis and at the level of double-basic residue proteolysis.Keywords
This publication has 27 references indexed in Scilit:
- Release of Catecholamines from Superfused Bovine Adrenal Chromaffin Cells Cultured on Microcarrier BeadsJournal of Neurochemistry, 1986
- Cholinergic Receptor‐Mediated Phosphorylation and Activation of Tyrosine Hydroxylase in Cultured Bovine Adrenal Chromaffin CellsJournal of Neurochemistry, 1986
- Tyrosine Hydroxylase in “Leaky” Adrenal Medullary Cells: Evidence for In Situ Phosphorylation by Separate Ca2+ and Cyclic AMP‐Dependent SystemsJournal of Neurochemistry, 1984
- The adrenal chromaffin cell as a model to study the co-secretion of enkephalins and catecholaminesJournal of the Autonomic Nervous System, 1983
- Met-Enkephalin [Arg6,Phe7] Immunoreactivity in Bovine Caudate and Bovine Adrenal MedullaJournal of Neurochemistry, 1982
- Enkephalin congeners and precursors are synthesized and released by primary cultures of adrenal chromaffin cellsLife Sciences, 1981
- Co-release of enkephalin and catecholamines from cultured adrenal chromaffin cellsNature, 1981
- Opioid peptides in adrenal glandLife Sciences, 1980
- Stability of Bovine Adrenal Medulla Cells in CultureJournal of Neurochemistry, 1980
- Release of enkephalin-like immunoreactive material from isolated bovine chromaff in cellsNeuropharmacology, 1980